A study released in BMC Public Health evaluated the use of coffee for chronic liver disease.
Conducted by the University of Southampton and Edinburgh, the study used the UK Biobank data to study close to 500,000 participants with frequent consumption of coffee. The participants were studied for a span of about 10 years.
The study focused on the use of decaffeinated, instant coffee when attempting to establish a relationship with its potential beneficiary effects for chronic liver disease.
“A total of 494,585 UK Biobank participants with known coffee consumption and electronic linkage to hospital, death and cancer records were included in this study,” researchers explained in their findings.
“Cox regression was used to estimate hazard ratios (HR) of incident chronic liver disease (CLD), incident CLD or steatosis, incident hepatocellular carcinoma (HCC) and death from CLD according to coffee consumption of any type as well as for decaffeinated, instant and ground coffee individually.”
The findings uncovered that all forms of coffee consumption may protect against chronic liver disease.
“The finding that all types of coffee are protective against CLD is significant given the increasing incidence of CLD worldwide and the potential of coffee as an intervention to prevent CLD onset or progression,” researchers concluded.